RIMLS highlights 2019
Biodegradable patches for children with congenital diaphragmatic hernia
Willeke Daamen and Toin van Kuppevelt received together with University of Twente a 690 kEuro grant of the Netherlands Organization for Scientific Research (NWO) for the development of advanced patches for closure of diaphragmatic defects in children with congenital diaphragmatic hernia.15 Million Euro to discover new avenues to fight the HIV virus
“This is a unique, first-time collaboration which will combine in-depth clinical and pathophysiological phenotyping with a systems biology approach in a large population of patients with HIV.” read more15 Million Euro to discover new avenues to fight the HIV virus
André van der Ven, Mihai Netea and colleagues, received 15 mEuro from the pharmaceutical company ViiV Healthcare to discover new avenues to fight the HIV virus. The aim of the HIV 2000+ project is to identify new drug targets for HIV. This collaboration will process anonymised patient data, genetic information and environmental factors in order to understand the biology associated with HIV better and identify targets for new medicines earlier.ViiV Healthcare is announcing a five-year collaboration with researchers of the Radboudumc, providing dedicated funding to enhance the HIV-specific capability of the Human Functional Genomics Project (HFGP). The HFGP is a large-scale project that combines detailed patient data with cross-omics information, host immune responses and environmental factors to better understand how the body recognizes and defends itself from disease as well as the signs, symptoms and progression of disease.
Under the supervision of a Scientific Management Board (SMB) comprising representatives from Radboudumc and ViiV Healthcare, Radboudumc will expand the cohort of HIV-infected individuals that are part of the HFGP from 200 to 2000 people. Data from this cohort will be used to look at the predictors and pathways of diseases that are specific to people living with HIV and how they might differ from other disease areas and from healthy people who do not have HIV. Using that information, the goal is to identify early stage drug targets that ViiV Healthcare could use to develop new medicines or approaches to treat HIV infection.
The project, called “HIV 2000+” will be the first comprehensive cohort study in HIV to use a field of biology called 'cross-omics,' which uses genomics, microbiome metagenomics and metabolomics technologies to better understand the underlying biology associated with HIV infection.
Jan van Lunzen, MD PhD, Head of Translational Medical Research at ViiV Healthcare and project coordinator said: “This project will enable us to establish one of the best characterized cohorts of people living with HIV in the world and will not only help to better define biomarkers and pathways of disease progression, but may also serve as a fantastic platform to find new drug targets.”
The collaboration will combine Radboudumc’s experience in infectious diseases, established networks and scientific techniques with ViiV Healthcare’s expertise and innovation in discovering and developing medicines for HIV.
Mihai Netea said: “This is a unique, first-time collaboration which will combine in-depth clinical and pathophysiological phenotyping with a systems biology approach in a large population of patients with HIV. It is a unique chance to understand the HIV infection and its complications better, and to partner with ViiV Healthcare to translate that knowledge to the bed of the patient.”
H2020 FET open grant for Frank Walboomers and Ronald Bartels
The FET Open supports research into radically new technologies. Frank and Ronald received the grant for their research into graphene biomaterials. read moreH2020 FET open grant for Frank Walboomers and Ronald Bartels
Frank Walboomers and Ronald Bartels have received a 500 kEuro grant for research into graphene biomaterials from the Europan Union Horizon 2020 FET Open programme.The FET Open supports research into radically new technologies. Spinal cord injury (SCI) is a devastating pathology with dramatic lifetime consequences affecting thousands of people worldwide. Considering the very limited regeneration ability of the central nervous system, the project will be focusing on the development of a neural tissue engineered scaffold capable of not only combining fibrous and porous topographic cues in order to mimic the morphology of the native spinal cord, but also potentiating the properties of graphene related materials (GRM). The obtained 3D microenvironment should present electrical, chemical, mechanical and topographic features able to preserve neural cell survival and enhance neural progenitor cell differentiation towards neuronal and glial cells.
The grant is part of a multidisciplinary pan European consortium and within the Radboudumc will join the specific expertises in Biomaterials and Neurosurgery to have a significant impact on healthcare.
ReumaNederland grant for Peter van der Kraan
Peter van der Kraan received 500 kEuro to study osteoarthritis. He is also awarded the title Research Center of Excellence by ReumaNederland. read moreReumaNederland grant for Peter van der Kraan
Peter van der Kraan received 500 kEuro to study cartilage damage and pain in knee osteoarthritis. Osteoarthritis is the most common rheumatic disorder. This project will form the basis for new treatments that help to reduce cartilage damage and pain due to osteoarthritis. The research group of Peter van der Kraan is also awarded the title Research Center of Excellence by ReumaNederland.With the Research Centers of Excellence at the forefront of osteoarthritis research, ReumaNederland aims to improve the treatment of people with osteoarthritis. Osteoarthritis affects nearly 1.4 million people in the Netherlands. Treatments are currently limited to lifestyle advice, pain relief and exercise therapy and, in the worst case, a prosthesis. In the coming period, a total of seven university research groups in the Netherlands will be named Research Centers of Excellence for osteoarthritis. Reuma Nederland provides a total of 3.8 mEuro for the Osteoarthritis Research Centers.
H2020 infrastructure development grant for a new EATRIS flagship project on personalized medicine
EATRIS, the European infrastructure for translational medicine, obtained funding for a new flagship project for sustainability and personalized medicine: EATRIS-Plus. Alain van Gool, Peter-Bram ‘t Hoen and Ariaan Siezen are co-PI’s. read moreH2020 infrastructure development grant for a new EATRIS flagship project on personalized medicine
EATRIS, the European infrastructure for translational medicine, obtained funding for a new flagship project for sustainability and personalized medicine: EATRIS-Plus. Alain van Gool (Mitochondrial diseases), Peter-Bram ‘t Hoen (Nanomedicine) and Ariaan Siezen received 550 kEuro from this 5 million Euro Horizon2020 infrastructure development grant.The project aims to build further capabilities and deliver innovative scientific tools to support the long-term sustainability of EATRIS. A key output of the project will be the piloting and delivery of a multi-omic toolbox, that will include SOPs, guidelines for best practices, reference materials, quality parameters, analysis tools, criteria for establishing reference values, and will provide access to a repository of multi-omic data. Objectives that are in line with the ambitions of the Netherlands X-omics Initiative, coordinated by Alain van Gool.
EATRIS covers over 90 institutes across Europe, among which Radboudumc. It has shown strong proof of concept of the value and utility of its translational medicine services portfolio, with users including academia, SMEs, large pharma, biotech and research funding organizations. The overarching aim of EATRIS-Plus is to further support the long-term sustainability of EATRIS by delivering innovative scientific tools to the personalized medicine research community. EATRIS-Plus will help pooling and utilising the translational academic capacities of the infrastructure in omics technologies to enable researchers to better address the scientific and societal challenges of personalized medicine.
List of grants
A selection of other grants obtained by our RIMLS researchers is presented here. read moreHorizon 2020 grants
A selection of Horizon 2020 grants obtained by our RIMLS researchers is presented here. read moreHorizon 2020 grants
Inflammatory diseases
H2020 grant: ImmUniverse: Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies. Irma JoostenTotal grant: 15.5 mEuro. Awarded Radboudumc: 1.1 mEuro.
H2020 grant: Brain injury in the premature born infant: stem cell regeneration research network (PREMSTEM). Renate van der Molen
Total grant: 9 mEuro. Awarded Radboudumc: 322 kEuro.
H2020 grant: BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis). Ellen van den Bogaard
Total grant: 10.5 mEuro. Awarded Radboudumc: 258 kEuro.
Infectious diseases and global health
H2020 grant: Coordinator of an international consortium to screen thousands of people with diabetes in Uganda and Tanzania for TB, and investigate the effect and costs of 3 months preventive treatment for TB. Reinout van Crevel and Lindsey te BrakeTotal grant: 4.8 mEuro. Awarded Radboudumc: 2 mEuro.
H2020 grant: Personalized immunotherapy in sepsis: a precision medicine-based approach (Immunosep). Mihai Netea
Total grant: 10 mEuro. Awarded Radboudumc: 1.6 mEuro.
H2020 grant: Host-targeted approaches for the prevention and the treatment of Hospital-Acquired Pneumonia (HAP2). Mihai Netea
Total grant: 10 mEuro. Awarded Radboudumc: 785 kEuro.
H2020 grant: Diagnosis and management of febrile illness using RNA personalized molecular signature diagnosis (DIAMONDS). Marien de Jonge
Total grant: 22.6 mEuro. Awarded Radboudumc: 400 kEuro.
H2020 grant: Prevention of antibiotic resistance by TARGEted Treatment of pneumonia in children. Marien de Jonge and Quirijn de Mast
Total grant: 787 kEuro. Awarded Radboudumc: 299 kEuro.
H2020-MSCA-ITN.grant: Deciphering the fungus-host-microbiota interplay to improve the management of fungal infections. Mihai Netea
Total grant: 3.5 mEuro. Awarded Radboudumc: 266 kEuro.
H2020-MSCA-ITN.grant: Cell2Cell: What makes a successful pathogen: Understanding the impact of cell-to-cell heterogeneity in chromatin structure on infection and adaptation. Richard Bartfai
Total grant: 3.9 mEuro. Awarded Radboud University: 266 kEuro.
H2020 grant: Revolutionizing healthcare by ytracking and understanding human cells during disease. Mihai Netea
Total grant: 1 mEuro. Awarded Radboudumc: 2.5 kEuro.
Mitochondrial diseases (Metabolic disorders)
H2020 grant: PD-MitoQUANT consortium. Werner KoopmanTotal grant: 4.5 mEuro. Awarded Radboudumc: 400 kEuro.
Nanomedicine
H2020 grant: HDM-FUN: Host directed medicine in invasive fungal infection. Frank van de VeerdonkTotal grant: 10 mEuro. Awarded Radboudumc: 2,8 mEuro.
H2020 grant: EATRIS-Plus. Consolidating the capacities of EATRIS-ERIC for Personalised Medicine. Alain van Gool, Peter-Bram ’t Hoen, Ariaan Siezen
Total grant: 5 mEuro. Awarded Radboudumc: 550 kEuro.
H2020 grant: ReCognitION: Recognition and Validation of Druggable Targets from the Response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks. Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon
Total grant: 1.3 mEuro. Awarded Radboudumc: 250 kEuro.
Reconstructive and regenerative medicine
H2020 FET open grant: Neurostimspinal: A step forward to spinal cord injury repair using innovative stimulated nanoengineered scaffolds. Frank WalboomersTotal grant: 3.5 mEuro. Awarded Radboudumc: 500 kEuro.
H2020Grant: European Commission 3HP. Wout Feitz
Total grant: 600 kEuro. Awarded Radboudumc: 600 kEuro.
Renal Disorders
H2020 grant: SCilS - Studying ciliary signaling in development and disease. Ronald RoepmanTotal grant: 3.7 mEuro. Awarded Radboudumc: 531 kEuro.
Tumours of the digestive tract
H2020 grant: European Commission CEF 2018 (190180). Nicoline HoogerbruggeTotal grant: 100 kEuro. Awarded Radboudumc: 100 kEuro.
H2020 grant: Improving diagnostics and grasping the disease mechanisms of rare hypomagnesemia in patients with CNNM2 mutations. Joost Hoenderop
Total grant: 1 mEuro. Awarded Radboudumc: 250 kEuro.
Personal grants
A selection of personal grants obtained by our RIMLS researchers is presented here. read morePersonal grants
Dekker grant
Trained innate immunity at the level of bone marrow progenitors as driver of atherosclerosis development. Siroon Bekkering, Vascular damageAwarded: 209 kEuro.
EMBO fellowship
RegulatioNFkB: Deciphering transcriptional regulation of NF-kB target genes using integrative omics approaches. Katarzyna Kliza, Cancer development and immune defenseAwarded: 77 kEuro.
ERC – Advanced
A new approach to immunotherapy. Carl Figdor, Cancer development and immune defenseAwarded: 2,5 mEuro.
Improving vaccinations for the elderly. Mihai Netea, Infectious diseases and global health
Awarded: 2,5 mEuro.
ERC Proof of Concept grant
Ex vivo cell labeling for in vivo imaging applied to cell therapy. Mangala Srinivas, NanomedineAwarded: 150 kEuro.
Kolff Junior postdoc grant
PRednisOne effectS on Podocytes; rEsolving the moleculaR enigma - The PROSPER stud. Jitske Jansen, Renal disordersAwarded: 225 kEuro.
Kolff Senior postdoc grant
Innate immune-regulating nanotherapy for renal transplantation. Raphael Duivenvoorden, Renal disordersAwarded: 375 kEuro.
KWF Young Investigator grant
Imaging tumor infiltrating CD8+ T‐cells in non‐small cell lung cancer patients. Erik Aarntzen, Tumors of the digestive tractAwarded: 365 kEuro.
Marie Curie Individual fellowship
RegulatioNFkB: Deciphering transcriptional regulation of NF-kB target genes using integrative omics approaches. Irene Santos, Cancer development and immune defenseAwarded: 187 kEuro.
NWO Rubicon
Linda is traveling to the United Kingdom, Newcastle University, Campus for Ageing and Vitality. Linda Heskamp, Urological cancersAwarded: 100 kEuro.
NWO – Veni
The role of the anti-inflammatory cytokines interleukin-37 and IL-38 for innate immune memory. Rob Arts, Infectious diseases and global healthAwarded: 250 kEuro.
The secret lives of parasites in hepatocytes during malaria infection. Annie Yang, Infectious diseases and global health
Awarded: 250 kEuro.
Alarmed monocytes with Janus-faced behavior as the driving force behind OA pathology. Martijn van den Bosch, Inflammatory diseases
Awarded: 250 kEuro.
The REPAIR study: Regeneration of kidnEy ePitheliAl cells crossIng boRders. Jitske Jansen, Renal disorders
Awarded: 250 kEuro.
NWO – Vidi
The malaria parasite’s fight against our immune system. Matthijs Jore, Cancer development and immune defenseAwarded: 800 kEuro.
How Intelligent is the Immune System? Johannes Textor, Infectious diseases and global health
Awarded: 800 kEuro.
Restoring the immune system to prevent cancer from spreading. Daniele Tauriello, Tumors of the digestive tract
Awarded: 800 kEuro.